Norodyl 100mg Tablets for Dogs

Main information

  • Trade name:
  • Norodyl 100mg Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Norodyl 100mg Tablets for Dogs
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • carprofen
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0318/001
  • Authorization date:
  • 23-03-2009
  • EU code:
  • UK/V/0318/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued21/07/2009–AN02479/2007

SUMMARYOFPRODUCTCHARACTERISTICS

1. NameoftheVeterinary MedicinalProduct

Norodyl100mgTabletsforDogs(UK&DK)

Paracarp100mgTabletsforDogs(Germany)

Norocarp 100mgTabletsforDogs(allotherCMS)

2. QualitativeandQuantitativeComposition

Eachtabletcontains:

ActiveIngredients

Carprofen 100 mg

Excipients

Tartrazine(E102) 1.2 mg

Forafulllistofexcipients,seesection6.1

3. PharmaceuticalForm

Tablet

Ayellowcirculartabletof8mmdiameter,100embossedononesideanda

singlebreaklineontheotherside.

Thetabletscanbedividedintoequalhalves.

4. ClinicalParticulars

4.1 TargetSpecies:

Dogs

4.2 IndicationsforUse, Specifying theTargetSpecies:

Inthedog:

Reductionofinflammationandpaincausedbymusculoskeletaldisordersand

degenerativejointdisease.

Asafollowuptoparenteralanalgesiainthemanagementofpostoperative

pain.

4.3 Contraindications:

Donotuseincats.

Donotuseinpregnantorlactatingbitches.

Donotuseinpuppieslessthan4 monthsofage.

Donotuseincaseofhypersensitivitytoactivesubstanceortoanyofthe

excipients.

Issued21/07/2009–AN02479/2007

Donotuseindogssufferingfromcardiac,hepaticorrenaldisease,where

thereisapossibilityofgastrointestinalulcerationorbleeding,orwherethere

isevidenceofablooddyscrasia.

4.4 SpecialWarningsforEachTargetSpecies:

Referto Sections4.3 and4.5.

4.5 SpecialPrecautionsforUse:

(i)SpecialPrecautionsforUseinAnimals

Useinageddogsmayinvolveadditionalrisk.

Ifsuchausecannotbeavoided,suchdogsmayrequireareduceddosageand

carefulclinicalmanagement.

Avoiduseinanydehydrated,hypovolaemicorhypotensivedog,asthereisa

potentialriskofincreasedrenaltoxicity.

NSAIDscancauseinhibitionofphagocytosisandhenceinthetreatmentof

inflammatoryconditionsassociatedwithbacterialinfection,appropriate

concurrentantimicrobialtherapyshouldbeinstigated.

Referto section4.8.

(ii)Specialprecautionstobetakenbythepersonadministeringthe

veterinary medicinalproductto animals

Intheeventofaccidentalingestionofthetablets,seekmedicaladviceand

showthedoctorthepackageleaflet.

Washhandsafterhandlingtheproduct.

4.6 AdverseReactions(Frequencyand Seriousness):

TypicalundesirableeffectsassociatedwithNSAIDssuchasvomiting,soft

faeces/diarrhoea,faecaloccultblood,lossofappetiteandlethargyhavebeen

reported.Theseadversereactionsoccurgenerallywithinthefirsttreatment

weekandareinmostcasestransientanddisappearfollowingterminationof

thetreatmentbutinveryrarecasesmaybeseriousorfatal.

Ifadversereactionsoccur,useoftheproductshouldbestoppedandtheadvice

ofaveterinarianshouldbesought.

AswithotherNSAIDsthereisariskofrarerenaloridiosyncratichepatic

adverseevents.

4.7 UseDuring Pregnancy, LactationorLay:

Studiesinlaboratoryspecies(ratandrabbit)haveshownevidenceof

foetotoxiceffectsofcarprofenatdosesclosetothetherapeuticdose.The

safetyoftheveterinarymedicinalproducthasnotbeenestablishedduring

pregnancyandlactation.Do notuseinpregnantorlactatingbitches.

Issued21/07/2009–AN02479/2007

4.8 InteractionwithotherMedicinalProductsand OtherFormsofInteraction:

DonotadministerotherNSAIDsandglucocorticoidsconcurrentlyorwithin

24hoursofeachother.SomeNSAIDsmaybehighlyboundtoplasma

proteinsandcompetewithotherhighlybounddrugswhichcanleadtotoxic

effects

Concurrentadministrationofpotentialnephrotoxicdrugsshouldbeavoided.

4.9 Amountsto beAdministered and Administration:

Fororaladministration.

4mgcarprofenperkgbodyweightperday.

Aninitialdoseof4mgcarprofenperkgbodyweightperdaygivenasasingle

doseorintwoequallydivideddoses.Thedailydosemaybereduced,subject

to clinicalresponse.

Durationoftreatmentwillbedependentupontheresponseseen.Long-term

treatmentshouldbeunderregularveterinarysupervision.

Donotexceedthestateddose.

Toextendanalgesicandanti-inflammatorycoverpost-operativelyparenteral

pre-operativetreatmentwithaninjectableCarprofenproductmaybefollowed

withNorodylTabletsat4mg/kg/dayforupto 5 days.

Returnanyhalvedtabletstotheblisterpack andusewithin48 hours.

4.10 Overdose(symptoms, emergencyprocedures, antidotes), ifnecessary:

Donotexceedthestateddose.Thereisnospecificantidoteforcarprofen

overdosagebutgeneralsupportivetherapy,asappliedtoclinicaloverdosage

withNSAIDsshouldbeapplied.

4.11 WithdrawalPeriod(s):

Notapplicable

5. PharmacologicalProperties

Pharmacotherapeuticgroup:Non-steroidalanti-inflammatorydrug

ATCVetCode:QM01AE91

5.1 Pharmacodynamicproperties:

Carprofen,(

)-6-chloro- 

-methylcarbazole-2-aceticacid,isanon-steroidal

anti-inflammatorydrug(NSAID).Itisaderivativeofphenylpropionicacid

andamemberofthearylpropionicacidclassofNSAIDs.Asarepresentative

ofthe2-arylpropionicfamily,itcontainsachiralcenteratC

ofthepropionic

moietyandtherefore,existsin2sterioisomericforms,the(+)-Sand(-)-R

enantiomers.Carprofenpossessanti-inflammatory,analgesicandanti-pyretic

activity.CarprofenlikemostotherNSAIDsisaninhibitoroftheenzyme

cyclo-oxygenaseofthearachidonicacidcascade.Howevertheinhibitionof

Issued21/07/2009–AN02479/2007

prostaglandinsynthesisbycarprofenisslightinrelationtoitsanti-

inflammatoryandanalgesicpotency.Theprecisemodeofactionofcarprofen

isnotclear.

5.2 Pharmacokineticproperties:

Absorptionisrapidwith>90%absorptionafteroraladministration.The

volumeofdistributionissmallandcarprofenishighlyboundtoplasma

proteins.Biotransformationofcarprofenoccursinthelivertoformtheester

glucuronideandtwo1-O-acyl-ÿ-D-glucuronidediastereoisomers.Theseare

secretedinthebiliarytractandexcretedinthefaeces.TheCmaxis28.51

µg/mlandtheAUCis237.33 µg/ml.hour.

6. PharmaceuticalParticulars

6.1 ListofExcipient(s):

Tartrazine(E102)

MicrocrystallineCellulose

LactoseMonohydrate

CroscarmelloseSodium

PovidoneK30

Sodiumlaurilsulphate

MagnesiumStearate

6.2 Incompatibilities:

Notapplicable.

6.3 Shelf-Life:

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:2 years

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25ºC.

Storeinadryplace.

Protectfromlight.

6.5 Natureand CompositionofImmediatePackaging:

NorodylTabletsaresuppliedineither:

PolypropyleneSnapSecureTubscontaining14,30or100tablets,sealedwith

alowdensitywhitePolyethyleneSnapSecureCap, or

Aluminium-Aluminiumblisterstripswithstripsof10tabletsincartons

containing10,20,30,50,60,70,100,140,180,200,250,280,300,500or

1000 tablets.

Issued21/07/2009–AN02479/2007

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinalProducts

orWasteMaterialsDerived FromtheUseofSuchProducts, ifappropriate:

Anyunusedproductorwastematerialshouldbedisposedofinaccordance

withnationalrequirements.

7. NameorCorporateNameandAddressorRegisteredPlaceofBusinessof

theMarketing AuthorisationHolder

Norbrook LaboratoriesLimited

StationWorks

CamloughRoad

Newry

Co. Down

BT35 6JP

NorthernIreland

8. FinalInformation

MarketingAuthorisationNumber: Vm02000/4282

DateofApprovalofSPC: 21 July2009

DateofRevisionofSPC: 21 July2009

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily." (see pic...

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

28-8-2018

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market.

FDA - U.S. Food and Drug Administration

14-8-2018

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix LLC, is voluntarily recalling lot: 112710 of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa capsules, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend to the consumer level. These products have been tested by the U.S. Food and Drug Administration (“FDA”) and found to be contaminated with High Microbial Loads. Additionally, this serves as a update to a previous press release posted on June 30th 2018, concerning Blissful...

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance, adopted

Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

22-6-2018

Metronidazole intravenous infusion 500 mg/100 mL bag

Metronidazole intravenous infusion 500 mg/100 mL bag

Shortage and althernative supply of Metronidazole intravenous infusion 500 mg/100 mL bag

Therapeutic Goods Administration - Australia

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

28-2-2018

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim Capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

12-12-2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

TGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98

Therapeutic Goods Administration - Australia

21-11-2018

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Active substance: Propagermanium) - Orphan designation - Commission Decision (2018)7810 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/103/18

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (Active substance: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA) - Transfer of orphan designation - Commission Decision (2018)5033 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/12/T/01

Europe -DG Health and Food Safety